{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-106312","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2026-09-09T20:10:18+00:00","discovered_at":"2026-09-09T20:13:16.665029+00:00","generated_at":"2026-09-09T20:13:29.959904+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Century Therapeutics appoints Joseph Truitt to board; CNTY-813 IND on track for Q4 2026","bullets":["Joseph Truitt appointed to board effective Sept 9, 2026; serves as Class I director, term to 2028 annual meeting.","Truitt is CEO of iECURE; receives initial option grant of 148,000 shares vesting over 36 months and $40,000 annual retainer.","CNTY-813 iPSC-derived islet replacement for T1D on track for IND submission in Q4 2026 after FDA pre-IND alignment.","CNTY-308 CD19-targeted CAR-iT therapy expected to enter clinic in 2026; both use Allo-Evasion 5.0 platform.","Truitt previously CEO of BioSpecifics and Achillion; also chairman of Larimar Therapeutics (LRMR)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-106312","json":"https://secwatch.observer/filing/0001104659-26-106312.json","markdown":"https://secwatch.observer/filing/0001104659-26-106312.md","text":"https://secwatch.observer/filing/0001104659-26-106312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/0001104659-26-106312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/tm2625030d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T20:13:29.959904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}